ArticlePediatric surgery international2018
Response to pulmonary vasodilators in infants with congenital diaphragmatic hernia.
Article in Pediatric surgery international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Ventricular function in congenital diaphragmatic hernia: a systematic review and meta-analysis.European journal of pediatrics · 2022Pooled it
- Management advances for congenital diaphragmatic hernia: integrating prenatal and postnatal perspectives.Translational pediatrics · 2024Review
- Prostaglandin-E1 infusion in persistent pulmonary hypertension of the newborn.Pediatric pulmonology · 2024Article
- Diagnosis, management and long term cardiovascular outcomes of phenotypic profiles in pulmonary hypertension associated with congenital diaphragmatic hernia.Frontiers in pediatrics · 2024Review
- Early nitric oxide is not associated with improved outcomes in congenital diaphragmatic hernia.Pediatric research · 2023Article
- Prediction of survival in infants with congenital diaphragmatic hernia and the response to inhaled nitric oxide.European journal of pediatrics · 2022Article
- Predicting treatment of pulmonary hypertension at discharge in infants with congenital diaphragmatic hernia.Journal of perinatology : official journal of the California Perinatal Association · 2022Article
- Congenital diaphragmatic hernia: a narrative review of controversies in neonatal management.Translational pediatrics · 2021Review
- Treatment of pulmonary hypertension during initial hospitalization in a multicenter cohort of infants with congenital diaphragmatic hernia (CDH).Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Inhaled nitric oxide use in neonates: Balancing what is evidence-based and what is physiologically sound.Nitric oxide : biology and chemistry · 2020Review
- Use of sildenafil in an infant with persistent pulmonary hypertension secondary to lung and renal hypoplasia - a case report.BMC pediatrics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital diaphragmatic hernia (CDH) is associated with lung hypoplasia, cardiac dysfunction and pulmonary hypertension. Inhaled nitric oxide (iNO) and milrinone are commonly used pulmonary vasodilators in CDH. We studied the hemodynamic effects of iNO and milrinone in infants with CDH.
methodsA retrospective chart review was performed of all CDH infants admitted to two regional perinatal centers and infants classified into three groups: No-iNO group; iNO-responders and iNO-nonresponders. Oxygenation and hemodynamic effects of iNO and milrinone were assessed by blood gases and echocardiography.
resultsFifty-four percent (39/72) of infants with CDH received iNO and 31% of these infants (12/39) had complete oxygenation response to iNO. Oxygenation response to iNO was not associated with a decrease in right ventricular pressures (RVP) or ECMO use. Four infants (33%) in the iNO-responder group and eight infants (30%) in the iNO-nonresponder group received milrinone. Milrinone lowered RVP and improved ejection fraction (EF). Response to iNO was associated with improved oxygenation to milrinone and increased survival following ECMO (67 vs. 20% among nonresponders).
conclusionsResponse to inhaled nitric oxide in combination with milrinone may be associated with improved oxygenation and better survival after ECMO in infants with CDH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.